|
Schizophrenia
|
0.340 |
Biomarker
|
disease |
BEFREE |
Strikingly, mice deficient in the glutamate synthetic enzyme glutaminase have CA1 hypoactivity and a SCZ-resilience profile, implicating glutamate-metabolizing enzymes.
|
29471549 |
2019 |
|
Schizophrenia
|
0.340 |
Biomarker
|
disease |
BEFREE |
A constitutive heterozygous reduction in GLS1 engenders in mice a model of schizophrenia resilience and associated increases in Gln, reductions in Glu and activity-dependent attenuation of excitatory synaptic transmission.
|
31326460 |
2019 |
|
Schizophrenia
|
0.340 |
AlteredExpression
|
disease |
BEFREE |
Studies of the glutamate metabolic pathway have been limited, although there is some evidence that excitatory amino acid transporter-2, glutamine synthetase, and glutaminase have altered expression in schizophrenia.
|
25315318 |
2015 |
|
Schizophrenia
|
0.340 |
GeneticVariation
|
disease |
BEFREE |
Increased plasma glutamate by antipsychotic medication and its relationship to glutaminase 1 and 2 genotypes in schizophrenia -- Juntendo University Schizophrenia Projects (JUSP).
|
17669570 |
2007 |
|
Liver Cirrhosis, Experimental
|
0.300 |
Biomarker
|
disease |
CTD_human |
Systems level analysis and identification of pathways and networks associated with liver fibrosis.
|
25380136 |
2014 |
|
Degenerative polyarthritis
|
0.300 |
Biomarker
|
disease |
CTD_human |
Mitochondrial dysregulation of osteoarthritic human articular chondrocytes analyzed by proteomics: a decrease in mitochondrial superoxide dismutase points to a redox imbalance.
|
18784066 |
2009 |
|
Osteoarthrosis Deformans
|
0.300 |
Biomarker
|
disease |
CTD_human |
Mitochondrial dysregulation of osteoarthritic human articular chondrocytes analyzed by proteomics: a decrease in mitochondrial superoxide dismutase points to a redox imbalance.
|
18784066 |
2009 |
|
Spontaneous abortion
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Gene expression in cultured endometrium from women with different outcomes following IVF.
|
18539642 |
2008 |
|
Abortion, Tubal
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Gene expression in cultured endometrium from women with different outcomes following IVF.
|
18539642 |
2008 |
|
Early Pregnancy Loss
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Gene expression in cultured endometrium from women with different outcomes following IVF.
|
18539642 |
2008 |
|
Miscarriage
|
0.300 |
Biomarker
|
disease |
CTD_human |
Gene expression in cultured endometrium from women with different outcomes following IVF.
|
18539642 |
2008 |
|
Epileptic encephalopathy
|
0.110 |
Biomarker
|
disease |
BEFREE |
Early neonatal epileptic encephalopathy with glutaminase deficiency and lethal outcome.
|
30575854 |
2019 |
|
Global developmental delay
|
0.110 |
GeneticVariation
|
disease |
BEFREE |
We report a de novo Ser482Cys gain-of-function variant in GLS encoding GLS associated with profound developmental delay and infantile cataract.
|
30239721 |
2019 |
|
Epileptic encephalopathy
|
0.110 |
Biomarker
|
disease |
HPO |
|
|
|
|
Global developmental delay
|
0.110 |
Biomarker
|
disease |
HPO |
|
|
|
|
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Triple-negative (TN) breast cancer (testing negative for estrogen, progesterone, and Her2 receptors) has elevated GLS protein levels and reportedly depends on exogenous glutamine and GLS activity for survival.
|
31541193 |
2020 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In this review, we explore the role of glutaminase in cancer, primarily focussing on breast cancer, address the role played by oncogenes and tumour suppressor genes in regulating glutaminase, and discuss current therapeutic approaches in targeting glutaminase.
|
31596504 |
2020 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Importantly, limiting endogenous glutamate levels by glutaminase inhibition can sensitize tumors without alterations in the Keap1/Nrf2 pathway to dietary restriction of NEAAs.
|
31813821 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Glutaminase isoenzymes are critical proteins to control glutaminolysis, a key metabolic pathway for cell proliferation and survival that directs neoplasms' fate.
|
31100352 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In this review, we explore the role of glutaminase in cancer, primarily focussing on breast cancer, address the role played by oncogenes and tumour suppressor genes in regulating glutaminase, and discuss current therapeutic approaches in targeting glutaminase.
|
31596504 |
2020 |
|
Carcinogenesis
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
High glutaminase (GLS;EC3.5.1.2) activity is an important pathophysiological phenomenon in tumorigenesis and metabolic disease.
|
31734463 |
2020 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Triple-negative (TN) breast cancer (testing negative for estrogen, progesterone, and Her2 receptors) has elevated GLS protein levels and reportedly depends on exogenous glutamine and GLS activity for survival.
|
31541193 |
2020 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
In this review, we explore the role of glutaminase in cancer, primarily focussing on breast cancer, address the role played by oncogenes and tumour suppressor genes in regulating glutaminase, and discuss current therapeutic approaches in targeting glutaminase.
|
31596504 |
2020 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
<sup>13</sup>C HR MAS MRS analysis of tumor tissue from CB-839-treated and untreated models receiving <sup>13</sup>C-labeled glutamine ([5-<sup>13</sup>C] Gln) shows that the glutaminase inhibitor CB-839 is causing an accumulation of glutamine (arrow up) in two PDX models representing luminal-like breast cancer (MAS98.06) and basal-like breast cancer (MAS98.12).
|
31088535 |
2019 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Transcriptional analyses revealed that the expression levels of genes linked to lipid metabolism were altered between sensitive and resistant cells and between breast cancer tissues (available from The Cancer Genome Atlas project) with low <i>versus</i> high glutaminase (<i>GLS</i>) gene expression.
|
31040181 |
2019 |